USA Medical Device Reimbursement Consultant Services
From Clearance to Revenue
For over 20 years, Mediclever has served as specialized medical device reimbursement consultants, guiding global medtech leaders through the complexities of the US healthcare system, from FDA clearance to predictable commercial revenue.
Achieving sustainable medtech market access in the US requires a dual focus on public (Medicare/Medicaid) and private (Commercial) payers. Our landscape analysis identifies:
Our US-based medical device reimbursement consultants identify the key decision-makers at CMS and major private payers (UnitedHealthcare, Anthem, Aetna) to lay out a realistic timeline for market access.
Payer-Centric Evidence Planning & Clinical Optimization
Major private insurers and assessment organizations like the Blue Cross Blue Shield Association’s TEC evaluate novel medtech through strict evidence lenses. Our consulting services align your clinical and economic generation with specific payer requirements:
Market Access Implementation & Code Applications
Moving from commercial strategy into practical market entry is where emerging tech often stalls. Our execution services clear the path for widespread provider adoption:
- CPT/HCPCS Application Management: Structuring, authoring, and managing code development submissions presented before the American Medical Association (AMA) CPT Editorial Panel and CMS.
- Provider Coding & Billing Guides: Building field-ready compliance materials that provide hospital billing departments and clinical coders with exact diagnostic and procedure parameters.
- Interim Hospital Funding Solutions: Capitalizing on short-term reimbursement pathways, including New Technology Add-On Payments (NTAP) for inpatient environments and Transitional Pass-Through (TPT) status for outpatients.
USA Healthcare Reimbursement FAQs
Which reimbursement pathways exist in the USA?
Primary pathways include CPT (Level I) and HCPCS (Level II) coding for professional services/supplies, MS-DRG for inpatient stays, APC for outpatient procedures, and Medicare NCD/LCD coverage policies.
How do medical devices obtain Medicare coverage in the USA?
Medicare coverage is established through National Coverage Determinations (NCDs) or Local Coverage Determinations (LCDs). To accelerate rollout timelines, manufacturers can target specialized modern frameworks like the CMS RAPID coverage pathway.
Can reimbursement be pursued before FDA clearance?
Yes. Waiting until after FDA clearance results in an extended revenue gap. Designing a thorough coding validation and payer strategy should initiate 12–24 months before anticipated clearance.
What are the 2026 coding updates for AI, Digital Health, and RPM?
The 2026 CPT code set includes new Category I codes for AI-driven diagnostic software and optimized frameworks for Remote Patient Monitoring (RPM). Our commercial strategy maximizes deployment within the RPM model by streamlining compliance for daily data transmission and monitoring thresholds.
What is the CMS RAPID pathway?
The Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway is an accelerated CMS initiative designed to minimize commercialization timelines for innovative medical hardware and digital health applications, allowing early access to Medicare beneficiary populations while longitudinal clinical evidence scales.
Why Mediclever for US Market Access?
We are not just analysts; we are hands-on advocates. Our expert reimbursement consultants balance the unique operational nuances between Medicare Advantage plans and traditional fee-for-service Medicare, navigating the distinct regional medical policies governed by regional Medicare Administrative Contractors (MACs).